VEGFA and non-small cell lung carcinoma: Collectively, these findings suggest that RES may be a potential drug that can be used to inhibit the progression of NSCLC by targeting and inhibiting the STAT3, HIF‐1α, and VEGF signaling pathway (Wang et al. 2020).